Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GALECTIN THERAPEUTICS INC.

(GALT)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/21/2022 01/24/2022 01/25/2022 01/26/2022 01/27/2022 Date
1.92(c) 1.98(c) 1.91(c) 1.87(c) 1.82(c) Last
205 056 373 524 108 276 114 848 169 306 Volume
-5.42% +3.13% -3.54% -2.09% -2.67% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -34,9 M - -
Net Debt 2021 - - -
P/E ratio 2021 -3,08x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -48,9 M - -
Net Debt 2022 - - -
P/E ratio 2022 -2,39x
Yield 2022 -
Capitalization 108 M 108 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 6
Free-Float 70,5%
More Financials
Company
Galectin Therapeutics Inc. is a biotechnology company that is focused on developing novel therapies to improve the lives of patients with chronic liver disease and cancer. The CompanyÔÇÖs product candidates include galectin-3 inhibitor, belapectin (GR-MD-02) and GM-CT-01. The CompanyÔÇÖs lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein which is directly involved in multiple... 
More about the company
All news about GALECTIN THERAPEUTICS INC.
01/06Galectin Therapeutics to Present at the H.C. Wainwright BioConnect Conference
AQ
2021Galectin Therapeutics Announces Closing of $10 Million in Debt Financing from Its Chair..
AQ
2021GALECTIN THERAPEUTICS : Announces Closing of $10 Million in Debt Financing from Its Chairm..
PU
2021GALECTIN THERAPEUTICS INC : Entry into a Material Definitive Agreement, Creation of a Dire..
AQ
2021Galectin Therapeutics Inc. announced that it has received $20 million in funding
CI
2021Galectin Therapeutics Discusses Corporate Transformation, Progress of NAVIGATE Trial an..
AQ
2021GALECTIN THERAPEUTICS INC : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
2021GALECTIN THERAPEUTICS : Thanks Kevin - Form 8-K
PU
2021GALECTIN THERAPEUTICS INC : Regulation FD Disclosure, Financial Statements and Exhibits (f..
AQ
2021GALECTIN THERAPEUTICS : Reports Financial Results for the Quarter Ended September 30, 2021..
PU
2021Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 202..
GL
2021GALECTIN THERAPEUTICS INC Management's Discussion and Analysis of Financial Condition ..
AQ
2021Galectin Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Mont..
CI
2021NORTH AMERICAN MORNING BRIEFING : Stock Futures -2-
DJ
2021Galectin Therapeutics to Present Six Scientific Abstracts at The Liver Meeting 2021, Ho..
AQ
More news
News in other languages on GALECTIN THERAPEUTICS INC.
2021Galectin obtient un financement par emprunt de 20 millions de dollars du président Rich..
2021La perte de Galectin Therapeutics se creuse au deuxième trimestre, mais l'entreprise es..
2021Galectin Therapeutics publie des données positives sur l'essai de l'association Belapec..
2021Les actions américaines terminent généralement en baisse alors que les principales banq..
2021CLOSE UPDATE : Les actions américaines ont terminé en grande partie à la baisse alors que ..
More news
Analyst Recommendations on GALECTIN THERAPEUTICS INC.
More recommendations
Chart GALECTIN THERAPEUTICS INC.
Duration : Period :
Galectin Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GALECTIN THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 1,82 $
Average target price 14,00 $
Spread / Average Target 669%
EPS Revisions
Managers and Directors
Joel Lewis President, Chief Executive Officer & Director
Jack W. Callicutt Chief Financial Officer & Secretary
Richard E. Uihlein Chairman
Pol F. Boudes Chief Medical Officer
Ezra R. lowe Executive Director-Clinical
Sector and Competitors
1st jan.Capi. (M$)
GALECTIN THERAPEUTICS INC.-12.08%108
MODERNA, INC.-41.48%60 258
LONZA GROUP AG-19.46%48 939
IQVIA HOLDINGS INC.-17.77%44 321
SEAGEN INC.-20.50%22 475
ICON PUBLIC LIMITED COMPANY-17.13%20 892